Background Gastric cancer is the fifth most common cancer worldwide. In" Western"
countries, most people are either diagnosed at an advanced stage, or develop a relapse …

Background Almost half of people with esophageal or gastroesophageal junction cancer
have metastatic disease at the time of diagnosis. Chemotherapy and targeted therapies are …

Purpose To compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil,
leucovorin, and irinotecan (FOLFIRI) as first-line treatments in patients with advanced gastric …

Background: The lack of a clear definition of the palliative care patient hampers the
comparison of results across different studies and impedes implementation of research …

Gastric cancer (GC) and gastroesophageal junction cancers (GEJCs) are the third leading
cause of cancer-related death worldwide. Although several studies have evaluated the …

Background Cetuximab plus irinotecan/folinic acid/5-fluorouracil (5-FU)(IF) was evaluated
as first-line treatment of patients with advanced gastric cancer and gastroesophageal …

Background Palliative systemic therapy can prolong life and reduce tumor-related symptoms
for patients with advanced esophagogastric cancer. However, side effects of treatment could …

Background Randomized controlled trials (RCTs) have demonstrated that low‐dose direct
oral anticoagulants (DOACs), including rivaroxaban and apixaban, may help reduce the …

Background Sunitinib monotherapy in pretreated patients with advanced gastric cancer
(AGC) was investigated. Preplanned analyses of tumour biomarkers on treatment outcome …

Abstract Background. The Trastuzumab for Gastric Cancer phase III trial demonstrated that
combining trastuzumab with chemotherapy significantly improved overall survival compared …